A new collaboration aims to develop VMX-C001 to treat severe bleeding in patients on anticoagulants, targeting a 2029 …
A new collaboration aims to develop VMX-C001 to treat severe bleeding in patients on anticoagulants, targeting a 2029 …
Continued program expansion strengthens potential to deliver an all-oral, pan-genotypic next-generation HCV therapy.
CEO Lamballe highlights strategic advances, upcoming trial readouts, and expansion of microbiome ecosystem therapies pipeline.
Commercial partnership targets scalability, 24/7 PET imaging product access, and future expansion for next-gen cancer diagnostics.
June 11 reveals critical progress across cell and gene therapies, metabolic disease drug research, and strategic industry partnerships …
Significant biotech advancements and industry collaborations define early June with a focus on live biotherapeutics, liquid biopsies, and …
Early clinical successes, new research on immune toxicities, and expanding partnerships underscore the evolving landscape of cell and …
Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
New pivotal trial milestones in multiple sclerosis and head and neck cancer, plus key collaboration and funding moves, …
Already a subscriber? Log in